Company / Cash & Equivalents
AXIM BIOTECHNOLOGIES, INC. Cash & Equivalents History
FY2011-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$47.3K
FY2022
5-year range
$47.3K / $2.1M
FY2018-FY2022
Trend
-97.4%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2M to $47,282 over the past 5 years.
Based on SEC 10-K filings.
$47,282 in FY2022 with a 10-year CAGR of +9.5%.
Declined from $2M to $47,282 over the past 5 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -53.0%
- 10-Year CAGR
- +9.5%
Key checks
Key Insights
- 5-year CAGR of -53.0%, indicating a declining trend.
- In FY2022, cash & equivalents decreased 97.4% year-over-year.
- Peak cash & equivalents was recorded in FY2017.
- Lowest cash & equivalents in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | $47.3K | -97.4% |
| FY2018 | $1.8M | -12.3% |
| FY2017 | $2.1M | +188.5% |
| FY2016 | $713.3K | +431.7% |
| FY2015 | $134.2K | +105545.7% |
| FY2013 | $127 | -99.3% |
| FY2012 | $19.1K | -17.3% |
| FY2011 | $23.1K | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026